At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 97 enrolled
Drug / intervention
ABT-199 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
In Brief
A Phase 1 clinical trial evaluating ABT-199 and Placebo for Lupus Erythematosus. Completed, enrolled 97 participants across 15 sites in 4 countries.
Detailed Summary
To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus
CountriesGermany, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartNov 2012
Primary CompletionJun 2015
TodayJul 2026
First PostedSep 18, 2012
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.8 years ago
Interventions
ABT-199drug
Tablet
Placeboother
Tablet